Reyes FJE, Mejía RSA

Language: Spanish
References: 24
Page: 255-260
PDF size: 165.65 Kb.

ABSTRACT

Background: urea (carbamide) is a low-molecular-weight endogenous metabolite with hygroscopic, keratolytic, and epidermal differentiation- regulating properties. It’s a fundamental component of the natural moisturizing factor (NMF), contributing to stratum corneum homeostasis by regulating transepidermal water loss, corneocyte cohesion, and physiological desquamation. Its effects are concentration-dependent, allowing its use as a humectant, exfoliant, or keratolytic agent.
Objective: this paper aims to re-evaluate urea’s clinical relevance in dermatological therapeutics and highlight its underrecognized potential within evidence-based frameworks.
Discussion: despite its established efficacy, safety, and cost-effectiveness, urea has been progressively displaced by newer topical agents, such as retinoids and hyaluronic acid derivatives. The popularity of these alternatives is largely influenced by commercial marketing and cosmetic trends. This has led to an underutilization of a molecule with well-documented benefits in managing chronic dermatoses including psoriasis, ichthyosis, atopic dermatitis, and xerosis. Additionally, urea facilitates enhanced dermal penetration of co-administered active agents, reinforcing its value in combination therapies.
Conclusion: urea deserves renewed attention in contemporary dermatological protocols, particularly in light of its multifaceted actions, accessibility, and robust clinical profile.

REFERENCES

1. Crizón Díaz DP y Franco Correa VE, Barrera cutánea y productosreparadores de la misma, Piel (Barcelona), 2018.

2. Verzì AE, Musumeci ML, Lacarrubba F y Micali G, History ofurea as a dermatological agent in clinical practice, Int J ClinPract 2020; 74:e13621.

3. Piquero-Casals J, Morgado-Carrasco D, Delgado J y GarreA, Indicaciones de la urea tópica en dermatología, Piel 2021;36(10):689-94.

4. Lacarrubba F, Verzì AE, Dinotta F y Micali G, 10% urea cream insenile xerosis: clinical and instrumental evaluation, J CosmetDermatol 2021; 20(Suppl. 1):5-8.

5. Ju T, Labib A, Vander Does A y Yosipovitch G, Therapeutics inchronic pruritus of unknown origin, Itch 2023; 8(1):e64.

6. Pavicic T, Steckmeier S, Kerscher M y Korting HC, Evidenz-basierteKosmetika: Konzept und Anwendung bei den ZielstellungenLicht-geschädigte Altershaut und Xerosis, Wien Klin Wochenschr2009; 121(13-14):431-9.

7. Kottner J, Lichterfeld A, Blume-Peytavi U y Kuhlmey A, Förderungder Hautgesundheit im Alter, Z Gerontol Geriatr 2015;48(3):231-6.

8. El Genedy-Kalyoncu M, Richter C, Surber C, Blume-PeytaviU y Kottner J, The effect of a basic skin care product on thestructural strength of the dermo-epidermal junction: an exploratory, randomised, controlled split-body trial, Int Wound J 2022;19(2):426-35.

9. Sánchez-Regaña M, Llambí-Mateos F, Salleras-Redonnet M,Iglesias Sancho M, Collgros Totosaus H y Umbert-Millet P, Laformulación magistral en la terapéutica dermatológica actual,Actas Dermosifiliogr 2012; 103(8):655-63.

10. Pardo Masferrer J, Murcia Mejía M, Vidal Fernández M et al.,Prophylaxis with a cream containing urea reduces the incidenceand severity of radio-induced dermatitis, Clin Transl Oncol 2010;12:43-8.

11. Holder HG y MacKay EM, The application of carbamide (urea)therapy in wound healing, Ann Surg 1939; 110(1):102-14.

12. Stambouli OB y Himeur Z, Queratodermias palmoplantares,emc-Podología 2012; 14(3):1-19.

13. Caccavale S, Boccellino MP, Brancaccio G, Alfano R y ArgenzianoG, Keratolytics can replace curettage in daylight photodynamictherapy for actinic keratosis on the face/scalp: a randomizedclinical trial, J Eur Acad Dermatol Venereol 2024; 38:594-601.

14. Calik J, Pilarski B, Migdał M y Sauer N, Evaluación de la queratinizaciónexcesiva en áreas acrales a través de la dermatoscopiacon polarización cruzada y polarización paralela: una escala dequeratinización dermatoscópica, J Clin Med 2023; 12(22):7077.

15. Shi TW, Zhang JA, Zhang XW, Yu HX, Tang YB y Yu JB, Combinationtreatment of oral terbinafine with topical terbinafine and10% urea ointment in hyperkeratotic type tinea pedis, Mycoses2014; 57(9):560-4.

16. Tanuma H, Tanuma M, Abe M y Kume H, Usefulness of lanoconazole(astatr) cream in the treatment of hyperkeratotic typetinea pedis, Mycoses 2001; 44(5):181-90.

17. Borelli C, Bielfeldt S, Borelli S, Schaller M y Korting HC, Creamor foam in pedal skin care: towards the ideal vehicle for ureaused against dry skin, Int J Cosmet Sci 2011; 33(1):37-43.

18. Hall JE y Guyton AC, Tratado de fisiología médica, 14ª ed., Barcelona,Elsevier, 2020.

19. Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichaelAJ et al., Fitzpatrick’s Dermatology in General Medicine,9ª ed., Nueva York, McGraw Hill, 2019.

20. Vestergaard C, Torrelo A y Christen-Zaech S, Clinical benefits ofbasic emollient therapy for the management of patients withxerosis cutis, Int J Dermatol 2025. doi: 10.1111/ijd.17792.

21. Abdelmeniem IM, El Eryan IM, Nofal A, Fouda I y Omar SS, Topicalcalcipotriol combined with urea 20% versus intralesionalinjection of triamcinolone acetonide, 5-fluorouracil, and methotrexatein the treatment of nail psoriasis: a comparative study,Dermatol Ther 2022; 35(9):e15660.

22. Treesirichod A, Chaithirayanon S, Chaikul T y Chansakulporn S,The randomized trials of 10% urea cream and 0.025% tretinoincream in the treatment of acanthosis nigricans, J DermatologTreat 2021; 32(7):837-42.

23. Treesirichod A, Thaneerat N y Kangvanskol W, A comparison ofthe efficacy and safety profiles of 10% salicylic acid and 10%urea creams in treating acanthosis nigricans in adolescents:a randomized double-blinded study, Arch Dermatol Res 2023;315(7):2091-7.

24. Treesirichod A, Chuenboonngarm S y Kritsanaviparkporn C, Theefficacy and safety of 20% urea cream and 10% urea creamin the treatment of acanthosis nigricans in adolescents: a randomizedcomparative double-blind study, J Cosmet Dermatol2022; 21(7):2859-64.